Royalty Pharma plc Files 8-K on Security Holder Vote
Ticker: RPRX · Form: 8-K · Filed: May 12, 2025 · CIK: 1802768
| Field | Detail |
|---|---|
| Company | Royalty Pharma PLC (RPRX) |
| Form Type | 8-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Royalty Pharma is having a shareholder vote on May 12th, details to follow.
AI Summary
On May 12, 2025, Royalty Pharma plc filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain specific details about the nature of the vote or any associated financial transactions.
Why It Matters
This filing signals that Royalty Pharma plc is engaging its shareholders on a specific matter requiring their approval, which could impact corporate governance or strategic decisions.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial risks or significant operational changes.
Key Players & Entities
- Royalty Pharma plc (company) — Registrant
- May 12, 2025 (date) — Date of earliest event reported
FAQ
What specific matter is being submitted for a vote of security holders?
The filing does not specify the exact matter being submitted for a vote of security holders.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 12, 2025.
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report the submission of matters to a vote of security holders.
What is the Commission File Number for Royalty Pharma plc?
The Commission File Number for Royalty Pharma plc is 001-39329.
Where is Royalty Pharma plc's principal executive office located?
Royalty Pharma plc's principal executive office is located at 110 East 59th Street, New York, New York 10022.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding Royalty Pharma plc (RPRX).